Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2021; 13(9): 1318-1337
Published online Sep 26, 2021. doi: 10.4252/wjsc.v13.i9.1318
Mesenchymal stem cells and COVID-19: What they do and what they can do
Ejlal Abu-El-Rub, Ramada R Khasawneh, Fatimah Almahasneh, Zaid Altaany, Nesreen Bataineh, Hana Zegallai, Saravanan Sekaran
Ejlal Abu-El-Rub, Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg R2H2A6, Canada
Ejlal Abu-El-Rub, Department of Physiology and Pathophysiology, Basic Medical Sciences, Yarmouk University, IRBID 21163, Jordan
Ramada R Khasawneh, Department of Anatomy and Histology, Basic Medical Sciences, Yarmouk University, IRBID 21163, Jordan
Fatimah Almahasneh, Department of Physiology and Pharmacology, Basic Medical Sciences, Yarmouk University, IRBID 21163, Jordan
Zaid Altaany, Department of Biochemistry and Genetics, Basic Medical Sciences, Yarmouk University, IRBID 21163, Jordan
Nesreen Bataineh, Department of Pathology, Basic Medical Sciences, Yarmouk University, IRBID 21163, Jordan
Hana Zegallai, Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg R2H2A6, Canada
Saravanan Sekaran, Department of Pharmacology, Saveetha Dental College and Hospitals to be University, Chennai 600077, India
Author contributions: Abu-El-Rub E and Altaany Z conceptualized the review subtopics; Abu-El-Rub E, Khasawneh RR, Almahasneh F, Altaany Z, Bataineh N, Zegallai H and Sekaran S collected the literature used to write the review and drafted the manuscript; Abu-El-Rub E, Almahasneh F and Sekaran S revised and formatted the content of the manuscript and verified spelling, punctuation and grammatical errors; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Authors of this manuscript have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ejlal Abu-El-Rub, PharmD, PhD, Assistant Professor, Department of Physiology and Pathophysiology, Faculty of Medicine, Yarmouk University, Shafiq Irshidat st, IRBID 21163, Jordan. ejlal.abuelrub@yu.edu.jo
Received: March 14, 2021
Peer-review started: March 15, 2021
First decision: June 5, 2021
Revised: June 15, 2021
Accepted: August 27, 2021
Article in press: August 27, 2021
Published online: September 26, 2021
Processing time: 187 Days and 9.9 Hours
Core Tip

Core Tip: Coronavirus disease 2019 (COVID-19) pandemic continues its rampant spread as more vengeant strains emerged in many countries. Severe cases of COVID-19 have been complicated by respiratory failure and multiple organ dysfunction with high mortality rate. Mesenchymal stem cells regenerative and anti-inflammatory abilities can be an innovative approach in repairing the damaged organs and improve the survival rate for critically ill COVID-19 patients.